Results 81 to 90 of about 44,168 (180)

Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study

Blood Cancer Journal
Hypomethylating agents (HMA) are indicated in the treatment of higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The combination of hypomethylating agents with venetoclax (Ven) has demonstrated promising results in ...
Alex Bataller, Koji Sasaki, Samuel Urrutia, Guillermo Montalban-Bravo, Alexandre Bazinet, Kelly Chien, Danielle Hammond, Ian M. Bouligny, Mahesh Swaminathan, Ghayas Issa, Nicholas Short, Naval Daver, Courtney D. DiNardo, Tapan Kadia, Elias Jabbour, Farhad Ravandi, Gail J. Roboz, Michael Savona, Elizabeth A. Griffiths, James McCloskey, Olatoyosi Odenike, Aram Oganesian, Harold N. Keer, Mohammad Azab, Hagop Kantarjian, Guillermo Garcia-Manero   +25 more
doaj   +1 more source

PPARγ-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AML

Blood Neoplasia
: The combination of the B-cell lymphoma 2 (BCL2) inhibitor venetoclax (VEN) and the hypomethylating agent decitabine (DEC; VEN/DEC) constitutes a primary therapeutic strategy for treating older adults with acute myeloid leukemia (AML).
Kotoko Yamatani, Tatsuro Watanabe, Kaori Saito, Abdullah Khasawneh, Abhishek Maiti, Zhihong Zeng, Kala Hayes, Shinya Kimura, Courtney D. DiNardo, Xiaoping Su, Shuko Nojiri, Yasushi Okazaki, Michael Andreeff, Marina Konopleva, Yoko Tabe   +14 more
doaj   +1 more source

Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia

Therapeutic Advances in Hematology
Background: Medical resources, especially blood products, were in short supply during the COVID-19. Less intensive therapy with hypomethylating agents/venetoclax (VEN) seems an effective treatment option for patients with acute myeloid leukemia (AML ...
Xuezhu Xu, Rui Liu, Hongli Chen, Ruoyu Yang, Gongzhizi Gao, Aili He, Fangxia Wang   +6 more
doaj   +1 more source

Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care?

Annals of Hematology
Hypomethylating agents (HMA) alone or in combination with venetoclax (VEN) are a mainstay for disease control in elderly acute myeloid leukemia (AML). We evaluated the non-inferiority of HMA monotherapy compared to HMA/VEN combination in 227 AML patients
Francesco Tarantini, Corinne Contento, Ernesto Vigna, Vera Carluccio, Giuseppina Greco, Crescenza Pasciolla, Lucia Ciuffreda, Giovanni Rossi, Marina Aurora Urbano, Alessandro D’Ambrosio, Lara Aprile, Vito Pier Gagliardi, Mario Delia, Immacolata Attolico, Paola Carluccio, Vincenzo Federico, Antonella Bruzzese, Nicola Di Renzo, Massimo Gentile, Giuseppe Tarantini, Anna Mele, Attilio Guarini, Lorella Maria Antonia Melillo, Angelo Michele Carella, Domenico Pastore, Ferdinando Frigeri, Alessandro Maggi, Cosimo Cumbo, Giorgina Specchia, Pellegrino Musto, Francesco Albano   +30 more
doaj   +1 more source

ESTUDO DE VIDA REAL COMPARANDO FLUDARABINA+ CITARABINA+ ANTRACICLINA COM E SEM VENETOCLAX, EM PACIENTES COM LEUCEMIA MIELOIDE AGUDA RECIDIVADO/REFRATÁRIO, EM UMA INSTITUIÇÃO PÚBLICA NO BRASIL.

Hematology, Transfusion and Cell Therapy
Introdução: A combinação do inibidor de BCL-2, Venetoclax (VEN), com poliquimioterapia tem sido explorada no tratamento da Leucemia Mieloide Aguda (LMA), especialmente em pacientes recidivados ou refratários (R/R). Estudos anteriores indicam que esquemas
MBV Lima, EP Noronha, EQ Crusoe, MA Salvino, FSBF Chagas, GA Oliveira, SN Freitas, JFSD Carmo, LKN Canuto, LBD Santos   +9 more
doaj   +1 more source

DP095 | INTERACTION BETWEEN APOPTOSIS, PHOSPHOINOSITIDE-DEPENDENT PATHWAYS, AND POTENTIAL IMPLICATIONS OF A NOVEL BCL2 MUTATION IN RESPONSE TO AZACITIDINE AND VENETOCLAX IN HIGH-RISK MYELODYSPLASTIC NEOPLASMS

Haematologica
Azacitidine (AZA) is a standard hypomethylating agent for high-risk Myelodysplastic Neoplasms (MDS). The addition of Venetoclax (VEN), a BCL-2 inhibitor, enhances its efficacy.
I. Casalin, E. Ceneri, A. De Stefano, A. Cappellini, S. Ratti, L. Manzoli, L. Cocco, A. Ferrari, G. Simonetti, G. Martinelli, F. Zingarelli, C. Comparin, M. Fogli, S. Paolini, S. Parisi, A. Curti, C. Finelli, M.Y. Follo   +17 more
doaj  

Venetoclax combined with intensive chemotherapy as induction chemotherapy in newly diagnosed AML with FLT3-ITD-mutation. [PDF]

Blood Cancer J
Liu Y, Bai G, Zhao X, Suo X, Bai Y, Zheng F, Zhao W, Peng H, Wang D, Zhao L, Liu J, Li L, Zhou Z, Mi Y, Liu K.   +14 more
europepmc   +1 more source

A Nomogram Prediction Model and Scoring System for Resistance in Acute Myeloid Leukemia Patients Treated with Venetoclax Combined with Hypomethylating Agents. [PDF]

Curr Oncol
Fan Q, Guo Y, Hui X, Zhang Y, Li J, Liang J, Wang Y.   +6 more
europepmc   +1 more source

Remodeling of the bone marrow vasculature induced by venetoclax and azacitidine damage. [PDF]

Blood
Ngo S, D'Agostino G, Papazoglou D, Mohamad Nor F, Finsterbusch K, Habel K, Ferrelli A, Anjos-Afonso F, Bonnet D.   +8 more
europepmc   +1 more source

Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy. [PDF]

Blood
Kennedy VE, Peretz CAC, Walia A, Chyla B, Sun Y, Hill JE, Tran E, Koh AD, Ferng TT, Pintar S, Jones M, Popescu B, Lomeli I, Chehab F, Murad N, John A, Roy RP, Olshen AB, Berryhill CA, Davis C, Angus SP, Rivera JM, Meshulam A, Stieglitz E, Joshi SK, Traer E, Dail M, Hamidi H, Altman JK, Daver NG, Levis MJ, McCloskey J, Perl AE, Smith CC.   +33 more
europepmc   +1 more source